Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

Blood (2022) 140 (Supplement 1): 192–194.

https://doi.org/10.1182/blood-2022-157244

Published: 2022

Journal Articles

Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML

Susan Branford, Naranie Shanmuganathan, Carol Wadham, Nur Hezrin Shahrin, Adelina Fernandes, Jinghua Feng, Andreas W Schreiber, Chung Hoow Kok, Verity A Saunders, Rob King, Ming Lin, Ilaria S Pagani, David T Yeung, David M Ross, Agnes S.M. Yong, Timothy Hughes

Blood (2022) 140 (Supplement 1): 3916–3917.

https://doi.org/10.1182/blood-2022-158735

Published: 2022

Journal Articles

KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure

David T Yeung, BSc, MBBS, FRACP, FRCPA, Ljiljana Vidovic, BSc, Carine Tang, BSc., (Hons) PhD, Deborah L White, PhD FFSc (RCPA), Susan Branford, PhD, Timothy P Hughes, MD MBBS, FRACP, FRCPA, Agnes S.M. Yong, MD PhD

Blood (2014) 124 (21): 814.

https://doi.org/10.1182/blood.V124.21.814.814

Published: 2014

Journal Articles

Effective Elimination of CML Progenitor and Stem Cells Through Combination of α-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment

Eva Nievergall, PhD, Deborah L. White, PhD, FFSc(RCPA), Agnes S.M. Yong, MD, PhD, Hayley S. Ramshaw, PhD, Samantha J. Busfield, PhD, Gino Vairo, PhD, Angel F. Lopez, MBBS, PhD, Timothy P. Hughes, MD, MBBS, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA

Blood (2012) 120 (21): 32.

https://doi.org/10.1182/blood.V120.21.32.32

Published: 2012

Journal Articles

Killing of Quiescent and Cycling Chronic Myeloid Leukemia CD34+ Cells by Autologous Ex-Vivo Expanded Natural Killer Cells Is Enhanced by Bortezomib Treatment.

Agnes S.M. Yong, MD, PhD, Nicole Stephens, BS, Keyvan Keyvanfar, BS, Bipin N. Savani, MD, Rhoda Eniafe, BS, Maria Berg, BS, Elaine M. Sloand, MD, Richard Childs, MD, A. John Barrett, MD

Blood (2010) 116 (21): 3395.

https://doi.org/10.1182/blood.V116.21.3395.3395

Published: 2010

Journal Articles

Primitive Quiescent CD34+ Cells in Chronic Myeloid Leukemia Are Targeted by In Vitro Expanded Allogeneic Natural Killer Cells, Which Are Functionally Enhanced by Bortezomib Treatment.

Agnes S.M. Yong, MD, PhD, Keyvan Keyvanfar, BS, Nancy Hensel, BS, Rhoda Eniafe, BS, Bipin N. Savani, MD, Maria Berg, BS, Andreas Lundqvist, PhD, Elaine M. Sloand, MD, John M. Goldman, MD, Richard W. Childs, MD, A. John Barrett, MD

Blood (2007) 110 (11): 1008.

https://doi.org/10.1182/blood.V110.11.1008.1008

Published: 2007

Journal Articles

Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT).

Mohamad Mohty, MD, PhD, Agnes S.M. Yong, MD, PhD, Richard M. Szydlo, PhD, Jane F. Apperley, MD, John M. Goldman, MD, Junia V. Melo, MD, PhD

Blood (2007) 110 (11): 464.

https://doi.org/10.1182/blood.V110.11.464.464

Published: 2007

Journal Articles

Leukemia-Associated Antigen Specific T-Cell Responses Following Combined PR1 and WT1 Peptide Vaccination in Patients with Myeloid Malignancies.

Katayoun Rezvani, MD, PhD, Agnes S.M. Yong, MD, PhD, Stephan Mielke, MD, Bipin N. Savani, MD, Laura Musse, Jeanine Superata, Behnam Jafarpour, MD, Carol Boss, A. John Barrett, MD

Blood (2007) 110 (11): 287.

https://doi.org/10.1182/blood.V110.11.287.287

Published: 2007

Journal Articles

Cytotoxic T Lymphocyte Responses to PR1 Peptide in Chronic Myeloid Leukemia Patients Inversely Correlate with Proteinase 3 and Elastase Expression but Donor PR1 Responses Determine Survival after Stem Cell Transplantation.

Agnes S.M. Yong, MD, PhD, Katayoun Rezvani, MD, PhD, Bipin N. Savani, MD, Rhoda Eniafe, BS, Stephan Mielke, MD, John M. Goldman, MD, A. John Barrett, MD

Blood (2006) 108 (11): 3697.

https://doi.org/10.1182/blood.V108.11.3697.3697

Published: 2006

Journal Articles

Hematopoietic Stem Cells and Primitive Progenitors Express Leukemia-Associated Antigens That May Be Targets for Graft-Versus-Leukemia Effect or for Vaccine-Based Immunotherapy in Chronic Myeloid Leukemia.

Agnes S.M. Yong, MD, PhD, Keyvan Keyvanfar, BS, Rhoda Eniafe, BS, Bipin N. Savani, MD, Elaine M. Sloand, MD, John M. Goldman, MD, A. John Barrett, MD

Blood (2006) 108 (11): 2125.

https://doi.org/10.1182/blood.V108.11.2125.2125

Published: 2006

Journal Articles

Molecular Profiling of CD34+ Cells from Diagnosis in CML Patients Identifies Low Expression of CD7 with High Expression of Proteinase 3 or Elastase as Predictors of Longer Survival.

Agnes S.M. Yong, MD, PhD, Richard M. Szydlo, PhD, John M. Goldman, MD, Jane F. Apperley, MD, Junia V. Melo, MD, PhD

Blood (2005) 106 (11): 1984.

https://doi.org/10.1182/blood.V106.11.1984.1984

Published: 2005

NARROW

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML

KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure

Effective Elimination of CML Progenitor and Stem Cells Through Combination of α-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment

Killing of Quiescent and Cycling Chronic Myeloid Leukemia CD34+ Cells by Autologous Ex-Vivo Expanded Natural Killer Cells Is Enhanced by Bortezomib Treatment.

Primitive Quiescent CD34+ Cells in Chronic Myeloid Leukemia Are Targeted by In Vitro Expanded Allogeneic Natural Killer Cells, Which Are Functionally Enhanced by Bortezomib Treatment.

Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT).

Leukemia-Associated Antigen Specific T-Cell Responses Following Combined PR1 and WT1 Peptide Vaccination in Patients with Myeloid Malignancies.

Cytotoxic T Lymphocyte Responses to PR1 Peptide in Chronic Myeloid Leukemia Patients Inversely Correlate with Proteinase 3 and Elastase Expression but Donor PR1 Responses Determine Survival after Stem Cell Transplantation.

Hematopoietic Stem Cells and Primitive Progenitors Express Leukemia-Associated Antigens That May Be Targets for Graft-Versus-Leukemia Effect or for Vaccine-Based Immunotherapy in Chronic Myeloid Leukemia.

Molecular Profiling of CD34+ Cells from Diagnosis in CML Patients Identifies Low Expression of CD7 with High Expression of Proteinase 3 or Elastase as Predictors of Longer Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only